These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 17043751)

  • 41. A review of sitaxsentan sodium in patients with pulmonary arterial hypertension.
    Waxman AB
    Vasc Health Risk Manag; 2007; 3(1):151-7. PubMed ID: 17583185
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of hypertension therapy based on eprosartan on systolic arterial blood pressure and cognitive function: primary results of the Observational Study on Cognitive function And Systolic Blood Pressure Reduction open-label study.
    Hanon O; Berrou JP; Negre-Pages L; Goch JH; Nádházi Z; Petrella R; Sedefdjian A; Sévenier F; Shlyakhto EV; Pathak A
    J Hypertens; 2008 Aug; 26(8):1642-50. PubMed ID: 18622244
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure: a comparison of selective and combined endothelin receptor blockade.
    Goddard J; Johnston NR; Hand MF; Cumming AD; Rabelink TJ; Rankin AJ; Webb DJ
    Circulation; 2004 Mar; 109(9):1186-93. PubMed ID: 14981006
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of dipeptidyl peptidase iv inhibition on arterial blood pressure.
    Jackson EK; Dubinion JH; Mi Z
    Clin Exp Pharmacol Physiol; 2008 Jan; 35(1):29-34. PubMed ID: 18047624
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Discovery, modeling, and human pharmacokinetics of N-(2-acetyl-4,6-dimethylphenyl)-3-(3,4-dimethylisoxazol-5-ylsulfamoyl)thiophene-2-carboxamide (TBC3711), a second generation, ETA selective, and orally bioavailable endothelin antagonist.
    Wu C; Decker ER; Blok N; Bui H; You TJ; Wang J; Bourgoyne AR; Knowles V; Berens KL; Holland GW; Brock TA; Dixon RA
    J Med Chem; 2004 Apr; 47(8):1969-86. PubMed ID: 15055997
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Human VIP-alpha: a long-acting, biocompatible and biodegradable peptide nanomedicine for essential hypertension.
    Onyüksel H; Séjourné F; Suzuki H; Rubinstein I
    Peptides; 2006 Sep; 27(9):2271-5. PubMed ID: 16621151
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Endothelin-1-like immunoreactivity in a new rodent model of spontaneous hypertension.
    Gulati A; Artwohl JE; Kumar A; Gao XP; Rubinstein I
    Am J Hypertens; 1998 Jul; 11(7):866-9. PubMed ID: 9683050
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Darusentan, a selective endothelin A receptor antagonist, for the oral treatment of resistant hypertension.
    Enseleit F; Lüscher TF; Ruschitzka F
    Ther Adv Cardiovasc Dis; 2010 Aug; 4(4):231-40. PubMed ID: 20660536
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Endothelin-A receptor inhibition after cardiopulmonary bypass: cytokines and receptor activation.
    Ford RL; Mains IM; Hilton EJ; Reeves ST; Stroud RE; Crawford FA; Ikonomidis JS; Spinale FG
    Ann Thorac Surg; 2008 Nov; 86(5):1576-83. PubMed ID: 19049753
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Initial characterization of hamsters with spontaneous hypertension.
    Thomas CL; Artwohl JE; Suzuki H; Gao X; White E; Saroli A; Bunte RM; Rubinstein I
    Hypertension; 1997 Aug; 30(2 Pt 1):301-4. PubMed ID: 9260996
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sitaxsentan-induced acute severe hepatitis treated with glucocorticoid therapy.
    Chin M; Levy RD; Yoshida EM; Byrne MF
    Can Respir J; 2012; 19(1):e1-2. PubMed ID: 22332138
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Causes of selectivity, activation and inhibition. Molecular mechanisms of endothelin-receptor recognition].
    Lättig J; Krause G
    Pharm Unserer Zeit; 2010 Nov; 39(6):442-7. PubMed ID: 20967932
    [No Abstract]   [Full Text] [Related]  

  • 53. Decrease of blood pressure in spontaneously hypertensive mice by heat treatment.
    Malo D; Pang SC; Schlager G; Tremblay J; Hamet P
    Am J Hypertens; 1990 May; 3(5 Pt 1):400-4. PubMed ID: 2350479
    [TBL] [Abstract][Full Text] [Related]  

  • 54. TBC 11251. IPI 1040.
    Drugs R D; 1999 Jul; 2(1):38-9. PubMed ID: 10610280
    [No Abstract]   [Full Text] [Related]  

  • 55. Pharmacologic renoprotection: are the stars finally moving into alignment?
    Stafford-Smith M
    Crit Care Med; 2011 Apr; 39(4):906-7. PubMed ID: 21613849
    [No Abstract]   [Full Text] [Related]  

  • 56. What is the impact of endothelin receptor blockade on atrial remodeling in a hypertensive model?
    Van Wagoner DR
    Int J Cardiol Heart Vasc; 2022 Oct; 42():101107. PubMed ID: 36042790
    [No Abstract]   [Full Text] [Related]  

  • 57. Selective endothelin A receptor antagonism with sitaxentan reduces neointimal lesion size in a mouse model of intraluminal injury.
    Duthie KM; Hadoke PW; Kirkby NS; Miller E; Ivy JR; McShane JF; Lim WG; Webb DJ
    Br J Pharmacol; 2015 Jun; 172(11):2827-37. PubMed ID: 25598351
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Sitaxentan: in pulmonary arterial hypertension.
    Scott LJ
    Drugs; 2007; 67(5):761-70; discussion 771-2. PubMed ID: 17385944
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prolonged anti-hypertensive effects of oral sitaxsentan, a selective ET(A) endothelin receptor antagonist, in spontaneoulsy hypertensive hamsters.
    Rubinstein I
    Cardiovasc Drugs Ther; 2006 Oct; 20(5):387-90. PubMed ID: 17043751
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Selective endothelin A receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease.
    Girgis RE; Frost AE; Hill NS; Horn EM; Langleben D; McLaughlin VV; Oudiz RJ; Robbins IM; Seibold JR; Shapiro S; Tapson VF; Barst RJ
    Ann Rheum Dis; 2007 Nov; 66(11):1467-72. PubMed ID: 17472992
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.